These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 2285275)

  • 21. Competition of various beta-lactam antibiotics for the major penicillin-binding proteins of Helicobacter pylori: antibacterial activity and effects on bacterial morphology.
    DeLoney CR; Schiller NL
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2702-9. PubMed ID: 10543750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy.
    Peitz U; Hackelsberger A; Malfertheiner P
    Drugs; 1999 Jun; 57(6):905-20. PubMed ID: 10400404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exposure to metronidazole in vivo readily induces resistance in Helicobacter pylori and reduces the efficacy of eradication therapy in mice.
    Jenks PJ; Labigne A; Ferrero RL
    Antimicrob Agents Chemother; 1999 Apr; 43(4):777-81. PubMed ID: 10103180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimicrobial therapies for Helicobacter pylori infection in gnotobiotic piglets.
    Krakowka S; Eaton KA; Leunk RD
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1549-54. PubMed ID: 9660981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of development of in vitro resistance to amoxicillin, clarithromycin, and metronidazole in Helicobacter pylori.
    Sörberg M; Hanberger H; Nilsson M; Björkman A; Nilsson LE
    Antimicrob Agents Chemother; 1998 May; 42(5):1222-8. PubMed ID: 9593154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Macrolide resistance in Helicobacter pylori: rapid detection of point mutations and assays of macrolide binding to ribosomes.
    Occhialini A; Urdaci M; Doucet-Populaire F; Bébéar CM; Lamouliatte H; Mégraud F
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2724-8. PubMed ID: 9420046
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Appearance of a metronidazole-resistant Helicobacter pylori strain in an infected-ICR-mouse model and difference in eradication of metronidazole-resistant and -sensitive strains.
    Matsumoto S; Washizuka Y; Matsumoto Y; Tawara S; Ikeda F; Yokota Y; Karita M
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2602-5. PubMed ID: 9420026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical application of gastric histology to monitor treatment of dual therapy in H. pylori eradication.
    Yang HB; Sheu BS; Su IJ; Chien CH; Lin XZ
    Dig Dis Sci; 1997 Sep; 42(9):1835-40. PubMed ID: 9331144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The population dynamics of antimicrobial chemotherapy.
    Lipsitch M; Levin BR
    Antimicrob Agents Chemother; 1997 Feb; 41(2):363-73. PubMed ID: 9021193
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.
    Hackelsberger A; Malfertheiner P
    Drug Saf; 1996 Jul; 15(1):30-52. PubMed ID: 8862962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic activities of metronidazole-sensitive and -resistant strains of Helicobacter pylori: repression of pyruvate oxidoreductase and expression of isocitrate lyase activity correlate with resistance.
    Hoffman PS; Goodwin A; Johnsen J; Magee K; Veldhuyzen van Zanten SJ
    J Bacteriol; 1996 Aug; 178(16):4822-9. PubMed ID: 8759844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro studies on stability and development of metronidazole resistance in Helicobacter pylori.
    van Zwet AA; Thijs JC; Schievink-de Vries W; Schiphuis J; Snijder JA
    Antimicrob Agents Chemother; 1994 Feb; 38(2):360-2. PubMed ID: 8192465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ribotyping patterns and emergence of metronidazole resistance in paired clinical samples of Helicobacter pylori.
    Rautelin H; Tee W; Seppälä K; Kosunen TU
    J Clin Microbiol; 1994 Apr; 32(4):1079-82. PubMed ID: 8027316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of rifaximin against Helicobacter pylori.
    Mégraud F; Bouffant F; Camou Juncas C
    Eur J Clin Microbiol Infect Dis; 1994 Feb; 13(2):184-6. PubMed ID: 8013497
    [No Abstract]   [Full Text] [Related]  

  • 35. Standardization of disk diffusion test and its clinical significance for susceptibility testing of metronidazole against Helicobacter pylori.
    Xia H; Keane CT; Beattie S; O'Morain CA
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2357-61. PubMed ID: 7840570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Explanations for high rates of eradication with triple therapy using metronidazole in patients harboring metronidazole-resistant Helicobacter pylori strains.
    van Zwet AA; Thijs JC; de Graaf B
    Antimicrob Agents Chemother; 1995 Jan; 39(1):250-2. PubMed ID: 7695317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eradication rate of Helicobcter pylori.
    Xia HY; Keane CT; O'Morain CA
    Gut; 1995 Oct; 37(4):591-2. PubMed ID: 7489957
    [No Abstract]   [Full Text] [Related]  

  • 38. In vitro activity of metronidazole against Helicobacter pylori as determined by agar dilution and agar diffusion.
    Knapp CC; Ludwig MD; Washington JA
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1230-1. PubMed ID: 1929268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Susceptibility of Helicobacter pylori to metronidazole.
    López-Brea M; Martín E; López-Lavid C; Sanz JC
    Eur J Clin Microbiol Infect Dis; 1991 Dec; 10(12):1082-3. PubMed ID: 1802703
    [No Abstract]   [Full Text] [Related]  

  • 40. Role of metronidazole resistance in therapy of Helicobacter pylori infections.
    Rautelin H; Seppälä K; Renkonen OV; Vainio U; Kosunen TU
    Antimicrob Agents Chemother; 1992 Jan; 36(1):163-6. PubMed ID: 1590683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.